Table 1.
Correlation between Bax protein level, Bax degradation activity (BDA), and tumor grade (Gleason score) in human prostate adenocarcinomas
| Tumor # | Gleason score | Bax protein | BDA | Bcl-2 protein |
|---|---|---|---|---|
| 1 | 3 | +++ | + | +++ |
| 2 | 5 | +++ | + | N/A |
| 3 | 5 | +++ | + | +++ |
| 4 | 6 | +++ | + | N/A |
| 5 | 6 | +++ | + | ++ |
| 6 | 6 | +++ | + | + |
| 7 | 6 | +++ | ++ | ++ |
| 8 | 7 | +++ | ++ | ++ |
| 9 | 7 | ++ | ++ | +++ |
| 10 | 7 | + | ++ | +++ |
| 11 | 7 | + | ++ | + |
| 12 | 7 | + | +++ | + |
| 13 | 8 | + | +++ | + |
| 14 | 9 | + | +++ | + |
| 15 | 9 | + | +++ | ++ |
| 16 | 10 | + | +++ | ++ |
Bax or Bcl-2 protein levels were assessed by immunoblot normalized to actin levels: +++, a strong signal; ++, a moderate signal; +, a weak signal; N/A, not available. BDA was assessed by comparison to control (buffer only) after 4-h incubation: +, <30% degradation; ++, 30–60% degradation; >60% degradation.